Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581912 | 0.89 | ADORA3 (0.51) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL20581904 | 0.86 | ADORA3 (0.54) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL22076468 | 0.84 | ADORA3 (0.59) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL23620836 | 0.84 | KDM4E (0.57) | KDM4EMEN1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL20581836 | 0.83 | ADORA3 (0.55) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL23620821 | 0.82 | ADORA3 (0.51) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL24344965 | 0.82 | KDM4E (0.50) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL20581913 | 0.81 | ADORA3 (0.53) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL23620820 | 0.80 | ADORA3 (0.42) | ADORA3KDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL23117590 | 0.79 | ADORA3 (0.51) | ADORA3ABCG2ABCB1ABCC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058698-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058698-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | ENPP2, MBOAT7, AADAC | ADORA3 3697/4885ABCG2 4677/4885ABCB1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.